The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1684 participants.
Also called NCT01665053
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,684 participants
- Sponsor
- Registry
-
NCT01665053
-
- Other papers using this trial's data
- Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents
- Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Italy, Japan, Latvia, Netherlands, New Zealand, Poland, Singapore, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01665053. Randomized; single masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2016-01-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
- Condition
- Coronary Artery Disease
- Intervention (Device)
- PROMUS Element Plus
- Intervention (Device)
- SYNERGY
- Lead sponsor
- Boston Scientific Corporation
Record details
- Record id
cardio:ct-nct01665053- Content hash
a64b1b2f9cdef952d282f0557dbccf47dc051da5a6aee6171e43e7823084fcc1